Latest Conference Articles

March 19th 2019, 9:03pm

SGO Annual Meeting

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics and associate vice president of clinical research at The University of Texas MD Anderson Cancer Center, discusses the promising results of the phase II innovaTV 201 study, in which tisotumab vedotin was used to treat patients with previously treated recurrent or metastatic cervical cancer.

March 19th 2019, 7:49pm

SGO Annual Meeting

Karen H. Lu, MD, professor and chair in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center discusses the challenges of risk-reducing salpingo-oophorectomy in women with an increased risk for hereditary ovarian cancer.

March 19th 2019, 2:19am

SGO Annual Meeting

Treatment with neratinib led to a clinical benefit rate of 54.5% in patients with HER2-mutant cervical cancer.

March 18th 2019, 8:45pm

SGO Annual Meeting

Jonathan Ledermann, MD, professor of medical oncology at UCL Cancer Institute in London, discusses the growing use of PARP inhibitors in maintenance therapy for ovarian cancer in an interview during the 2019 SGO Annual Meeting.

March 18th 2019, 7:48pm

SGO Annual Meeting

Combination therapy with pembrolizumab, bevacizumab, and metronomic cyclophosphamide induced a 95% disease control rate and 40% overall response rate among women with recurrent ovarian cancer.

March 18th 2019, 7:02pm

SGO Annual Meeting

Lenvatinib in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate.

March 18th 2019, 6:42pm

SGO Annual Meeting

Emese Zsiros, MD, PhD, discusses the results of her recent phase II trial that set out to evaluate the use of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

March 18th 2019, 12:07am

SGO Annual Meeting

Kathleen N. Moore, MD, associate director for clinical research, gynecologic oncologist at The Stephenson Cancer Center, The University of Oklahoma, explores the impact of the SOLO-1 trial in the field of ovarian cancer, in particular, the benefits olaparib provides and the light it shines on the importance of using genetic testing to inform treatment decisions.

March 17th 2019, 7:45pm

SGO Annual Meeting

Adverse events decreased among patients with high-risk ovarian cancer who received a 200- or 300-mg individualized starting dose of niraparib, based upon baseline bodyweight and platelet count, compared with a 300-mg fixed starting dose.

March 17th 2019, 6:10pm

SGO Annual Meeting

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, suggesting that repeat use could become more common.

March 17th 2019, 5:24pm

SGO Annual Meeting

Robert Coleman, MD, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the effect of age on the efficacy of rucaparib (Rubraca) in patients with recurrent ovarian carcinoma.

March 17th 2019, 1:52am

SGO Annual Meeting

Patients with recurrent ovarian cancer who received niraparib maintenance therapy experienced more progression-free time without experiencing symptoms or toxicity compared with placebo; the benefit was 4-fold for those with germline (g) BRCA-mutated disease and 2-fold for non-gBRCA-mutated ovarian cancer.

March 14th 2019, 11:02pm

PER® Miami Breast Cancer Conference

Blood-based biomarkers offer great potential for use in the management of breast and other cancers.

March 14th 2019, 12:04am

PER® Miami Breast Cancer Conference

David M. Euhus, MD, discusses a new trio of genes entering the risk assessment equation in hereditary breast cancer.

March 13th 2019, 8:43pm

PER® Miami Breast Cancer Conference

Identifying patients with ductal carcinoma in situ who are more likely to develop invasive breast cancer remains a challenge, despite decades of research and the development of stratification methods to predict progression and recurrence.

March 12th 2019, 8:04pm

PER® Miami Breast Cancer Conference

There has been much progress in the treatment of estrogen receptor-positive metastatic breast cancer over the past 40 years, and novel therapies are further expanding therapeutic options.

March 12th 2019, 6:48pm

PER® Miami Breast Cancer Conference

CtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.

March 10th 2019, 3:21am

PER® Miami Breast Cancer Conference

Although the first checkpoint inhibitor has just been approved for patients with breast cancer, findings from dozens of ongoing studies may eventually change the paradigm for large subsets of those with the malignancy.

March 10th 2019, 2:56am

PER® Miami Breast Cancer Conference

The development of antibody-drug conjugates represents a promising strategy for patients with metastatic triple-negative breast cancer, with early clinical trial results suggesting that novel agents could eventually change the landscape for this patient population.

March 10th 2019, 2:45am

PER® Miami Breast Cancer Conference

With tremendous advances and the accelerated approval of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, provider education in identifying associated toxicities from checkpoint inhibitor therapy is critical.